| 标题： | JAK抑制剂治疗风湿免疫病超药品说明书用药中国专家共识 |
| title： | Chinese Experts Consensus for Off-label Use of JAK inhibitors in the treatment of rheumatic diseases |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 各级临床医生（风湿病、儿科、药学和其他相关领域） |
| Guide users： | Clinical physicians at all levels (rheumatology, pediatrics, pharmacy, and other relevant fields) |
| 证据分级方法： | 检索国外药品说明书，MICROMEDEX数据库，临床指南、共识、临床研究等方面相关文献，收集JAK抑制剂治疗风湿免疫病超药品说明书用药相关证据, 参照 Micromedex 的 Thomson 分级系统标准，对有效性等级、推荐等级及证据等级三方面进行评价。组织风湿病学专家、儿科专家、药学专家，结合循证医学证据，通过德尔菲法评估优化达成共识。 |
| Evidence grading method： | Relevant evidence on drug label, guidelines, consensuses, MICROMEDEX database, clinical studies are collected and evaluated. We evaluate the effectiveness grade, recommendation grade and evidence grade by referring to the Thomson classification system standard of Micromedex.In combination with evidence, experts of rheumatology, pediatrics and pharmacy are inquiried,and reach a consensus through the evaluation and optimization of the Delphi method. |
| 制定单位： | 中山大学孙逸仙纪念医院 |
| Formulating unit： | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University |
| 注册时间： | 2022-06-09 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN321 |
| Registration number： | |
| 指南制订的目的： | JAK抑制剂超说明书用于各种风湿免疫病的应用报道近年爆发式涌现。然而，JAKi的安全性问题近年正引起临床关注，因此，有必要对JAK抑制剂超说明书用法形成专家共识，旨在进一步规范JAKi超药品说明书治疗风湿免疫病的临床应用。 |
| Purpose of the guideline： | The Off-label Use of JAK inhibitors in the treatment of various rheumatic diseases are increasing,but the safety concerns deserves great attention.Therefore, it is necessary to form an expert consensus on the Off-label use of JAK inhibitors, in order to further standardize the clinical application of JAK inhibitors in the treatment of rheumatic diseases. |
